NIDA-CTN-0052

This was a randomized, controlled pilot trial in which 62 inpatient/residential participants were recruited from six sites to participate in a study comparing buspirone to placebo. The purpose of this study was to evaluate buspirone's efficacy, relative to placebo, in blocking reinstatement of cocaine use as assessed by the maximum days of continuous cocaine abstinence, as assessed by twice-weekly UDS and self-report, during study weeks 4-15. The study also evaluated the impact of buspirone, relative to placebo, on other drug-abuse outcomes and on factors that may mediate buspirone’s efficacy as a relapse-prevention treatment.